Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases

Hematological Oncology

Volumn 26, Issue 4, 2008, Pages 235-239

  Alonci, A ^a   Allegra, A ^a   Bellomo, G ^a   Penna, G ^a   D'Angelo, A ^a   Quartarone, E ^a   Musolino, C ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Angiogenesis; Chronic myeloproliferative diseases; Circulating endothelial cells; VEGF; VEGFR2

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ARTICLE; CELL COUNT; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ERYTHROCYTE COUNT; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; THROMBOCYTHEMIA; AGED; BLOOD; CYTOLOGY; HEMATOPOIETIC STEM CELL; MIDDLE AGED;

AGED; CHRONIC DISEASE; ENDOTHELIAL CELLS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 58949103516     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.865     Document Type: Article

References (54)

1. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukaemia. Am J Pathol 1997; 150: 815-821.
2. Dilly SA, Jagger CJ. Bone marrow stromal cell changes in haematological malignancies. J Clin Pathol 1990; 43: 942-946.
3. Fiedler W, Graeven U, Ergun S. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukaemia. Blood 1997; 89: 1870-1875.
4. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000; 14: 1414-1418.
5. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
6. Kvasnicka HM, Thiele J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol 2004; 19: 1245-1260.
7. Ni H, Barosi G, Hoffman R. Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibbrosis. Am J Clin Pathol 2006; 126: 241-247.
8. Kini AR, Peterson LAC, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukaemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001; 12: 3919-3924.
9. Rajkumar SV, Mesa RA, Fonseca R. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amiloidosis. Clin Cancer Res 2002; 8: 2210-2216.
10. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
11. Vacca A, Di Loreto M, Ribatti D, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995; 50: 9-14.
12. Vacca A, Ribatti D, Iurlaro M, et al. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration morphogenesis, and angiogenesis. Int J Clin Lab Res 1998; 28: 55-68.
13. George J, Shmilovich H, deutsch V, Miller H, Keren G, Roth A. Comparative analysis of method for assessment of circulating endothelial progenitor cells. Tissue Eng 2006; 2: 1-5.
14. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658-3661.
15. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate of angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001; 61: 4341-4344.
16. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9: 702-712.
17. Lyden D, Hattory K, Dias S, et al. Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
18. De Bont ES, Guikema JE, Scerpen F, et al. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/ severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. Cancer Res 2001; 61: 7654-7659.
19. Beerepoot LV, Mehra N, Vermmat JSP, Zonnbenberg BA, Gebbink MFGB, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004; 15: 139-145.
20. Pelosi E, Valtieri M, Coppola S, et al. Identification of the hemangiobalst in postnatal life. Blood 2002; 100: 3203-3208.
21. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8: 498-508.
22. Wierzbowska A, Robak T, Krawczynska A, et al. Circulating endothelial cells in patients with acute myeloid leukaemia. Eur J Haematol 2005; 75: 492-497.
23. Liesveld JL, Rosell KE, Lu C, et al. Acute myelogenous leukaemia- microenvironment interactions: role of endothelial cells and proteasome inhibition. Haematology 2005; 10: 483-494.
24. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105: 3286-3294.
25. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006; 107: 2531-2535.
26. Gunsilius E. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Adv Exp Med Biol 2003; 522: 17-24.
27. Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250-259.
28. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukaemia. Blood 2000; 95: 309-313.
29. Pedro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukaemia. Blood 2000; 95: 2637-2644.
30. Fiedler W, Graeven U, Suleyman E, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukaemia. Blood 1997; 6: 1870-1875.
31. Schuch G, Machluf M, Bartsch G Jr, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukaemia in vivo. Blood 2002; 13: 4622-4668.
32. Xu D, Meng FY, Zhang Y. Expression of vascular endothelial growth factor in bone marrow cells of patients with acute myeloid leukemia. Di Yi Jun Da Xue Xue Bao 2002; 22: 357-359.
33. Xu D, Meng FY, Yi Zs. Role of vascular endothelial growth factor (VEGF) in development and progress of refractory acute myeloid leukaemia. Ai Zheng 2003; 22: 844-848.
34. He R, Liu B, Yang C, Yang RC, Tobelem G, Han ZC. Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence. Cancer Gene Ther 2003; 10: 879-886.
35. Ratajczak MZ, Ratajczak J, Machalinski B, et al. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth. Br J Haematol 1998; 103: 969-979.
36. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic proliferation and migration. J Clin Invest 2000; 106: 511-521.
37. Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukaemia. Blood 2000; 96: 768-770.
38. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717-3721.
39. Verstovsek S, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular endothelial growth factor expression in chronic phase chronic myeloid leukaemia. Blood 2002; 6: 2265-2267.
40. Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukaemia. Blood 2004; 2: 495-501.
41. Anderson KC. Moving disease biology from the laboratory to the clinic. Semin Oncol 2002; 29: 17-20.
42. Fusetti L, Pruneri G, Gobbi A, et al. Cancer Res 2000; 60: 2527-2534.
43. Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative disease. In World Health Organization Classification of Tumours: Tumours of the Haemopoietic and Lymphoid Tissue, Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). International Agency for Research on Cancer (IARC) Press: Lyon, France, 2001; 17-44.
44. Tefferi A, Thiele J, Orazi A, et al. Proposal and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primari myelofibrosis: recommendations from an ad hoc international export panel. Blood 2007; 110: 1092-1097.
45. Xu M, Bruno E, Chao J, et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 2005; 105: 1699-1705.
46. Andreasson B, Swolin B, Kutti J. Increase of CD34 positive cells in polycythaemia vera. Eur J Haematol 1997; 59: 171-176.
47. Andreasson B, Swolin B, Kutti J. Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Hematol 2002; 68: 189-193.
48. Bai J, Shao ZH, Liu H, et al. Apoptosis and proliferation of CD34 positive bone marrow cells in patients with polycythemia vera. Zhonghua Xue Ye Xue Za Zhi. 2004; 25: 195-197.
49. Leibundgut EO, Horn MP, Brunold C, et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica 2006; 91: 1465-1472.
50. Bompais H, Chagraoui J, Canron X, et al. Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood 2004; 7: 2577-2584.
51. Panteli K, Bai M, Hetzimichael E, Zagorianakou N, Agnantis NJ, Bourantas K. Serum levels and bone marrow immunohistochemical expression of vascular endothelial growth factor in patients with chronic myeloproliferative disease. Haematology 2007; 1: 148-155.
52. Verstousek S, Quintas-Cardona A, Kantarjian H, Tafferi A. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs 2006; 15: 1555-1563.
53. Dingli D, Mesa RA, Tafferi A. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med 2004; 43: 540-547.
54. Kastritis E, Dinopoulos MA. The evolving role of lenalidomide in the treatment of haematological malignancies. Expert Opin Pharmacother 2007; 8: 497-509.